A Single-center Prospective Measurement of Upper Extremity Function in Multiple Sclerosis Patients With Advanced Disability Treated With Ocrevus
Latest Information Update: 12 Dec 2024
At a glance
- Drugs Ocrelizumab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
Most Recent Events
- 28 Oct 2024 Status changed from active, no longer recruiting to completed.
- 02 Nov 2022 Planned End Date changed from 1 Dec 2022 to 1 Dec 2023.
- 02 Nov 2022 Planned primary completion date changed from 1 Dec 2022 to 1 Feb 2023.